RUNX1 transactivates BCR‐ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia

The emergence of tyrosine kinase inhibitors as part of a front‐line treatment has greatly improved the clinical outcome of the patients with Ph(+) acute lymphoblastic leukemia (ALL). However, a portion of them still become refractory to the therapy mainly through acquiring mutations in the BCR‐ABL1...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Tatsuya, Maeda, Shintaro, Shimada, Sae, Sakuramoto, Naoya, Morita, Ken, Koyama, Asami, Suzuki, Kensho, Mitsuda, Yoshihide, Matsuo, Hidemasa, Kubota, Hirohito, Kato, Itaru, Tanaka, Kuniaki, Takita, Junko, Hirata, Masahiro, Kataoka, Tatsuki R, Nakahata, Tatsutoshi, Adachi, Souichi, Hirai, Hideyo, Mizuta, Shuichi, Naka, Kazuhito, Imai, Yoichi, Kimura, Shinya, Sugiyama, Hiroshi, Kamikubo, Yasuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819354/
https://www.ncbi.nlm.nih.gov/pubmed/34902205
http://dx.doi.org/10.1111/cas.15239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819354/
https://www.ncbi.nlm.nih.gov/pubmed/34902205
http://dx.doi.org/10.1111/cas.15239

Ejemplares similares